Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination

Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination

Background: The efficacy and safety of asunaprevir + daclatasvir combination therapy for treatment of hepatitis C virus (HCV) in compensated cirrhotic patients was not fully evaluated in real-world. Outcomes were assessed in cirrhotic patients with sustained viral response (SVR). Material and method...

Full description

Bibliographic Details
Main Authors: Akihiro Tamori, Hoang Hai, Sawako Uchida-Kobayashi, Masaru Enomoto, Ritsuzo Kozuka, Hiroyuki Motoyama, Etsushi Kawamura, Atsushi Hagihara, Yuga Teranishi, Kanako Yoshida, Hiroyasu Morikawa, Yoshiki Murakami, Norifumi Kawada
Format: Article
Language:English
Published: Elsevier 2017-09-01
Series:Annals of Hepatology
Subjects:
Adverse events
Hepatocellular carcinoma
Resistance-associated substitution
Sustained viral response
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119304326

Internet

http://www.sciencedirect.com/science/article/pii/S1665268119304326

Similar Items